The complement system is recognised as a protector against blood-borne pathogens and a
controller of immune system and tissue homoeostasis. However, dysregulated complement …

Cyclic peptides are molecules that are already used as drugs in therapies approved for
various pharmacological activities, for example, as antibiotics, antifungals, anticancer, and …

Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital
myasthenic syndromes (CMS) represent an etiologically heterogeneous group of (very) rare …

Introduction The complement system is a key component of the innate immune system, and
its aberrant activation underlies the pathophysiology of various diseases. Zilucoplan is a …

Myasthenia gravis (MG) is an autoimmune disorder that affects the neuromuscular junction,
leading to muscle weakness and fatigue. MG is caused by antibodies against the …

Myasthenia gravis (MG) is a neuromuscular disease that results in compromised
transmission of electrical signals at the neuromuscular junction (NMJ) from motor neurons to …

Background Generalized myasthenia gravis (MG) with antibodies against the acetylcholine
receptor is a chronic disease causing muscle weakness. Access to novel treatments …

OBJECTIVE Autoimmune neurologic disorders encompass a broad category of diseases
characterized by immune system attack of the central, peripheral, or autonomic nervous …

Current drug treatment of myasthenia gravis : Current Opinion in Neurology Current drug
treatment of myasthenia gravis : Current Opinion in Neurology Log in or Register Subscribe to …

Comment 370 www. thelancet. com/neurology Vol 22 May 2023 in the prodromal phase.
Third, demonstrate target engagement to identify treatment outcome objectively and enable …